Insmed Incorporated
INSM
Rankning i aktier
#1111
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Aktiekurs
$95.88
Senast synkroniserad: 2026-10-20
Marknadsvärde
$20.94B
Förändring (1 dag)
0.61%
Förändring (1 år)
-42.00%
Land
US
Handel Insmed Incorporated (INSM)
Kategori
Healthcare
Antal utestående aktier för Insmed Incorporated (INSM)
Antal utestående aktier per June 2026: 217.35M
Enligt de senaste finansiella rapporterna och aktiekursen för Insmed Incorporated är det aktuella antalet utestående aktier 217.35M. I slutet av December 2023 hade företaget 140.43M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för Insmed Incorporated (INSM) från 2000 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 217.35M | 32.50% |
| 2024 | 164.04M | 16.81% |
| 2023 | 140.43M | 14.14% |
| 2022 | 123.04M | 9.74% |
| 2021 | 112.11M | 14.86% |
| 2020 | 97.61M | 15.43% |
| 2019 | 84.56M | 10.04% |
| 2018 | 76.84M | 15.42% |
| 2017 | 66.58M | 7.64% |
| 2016 | 61.85M | 5.72% |
| 2015 | 58.51M | 35.99% |
| 2014 | 43.02M | 22.99% |
| 2013 | 34.98M | 31.89% |
| 2012 | 26.52M | 13.59% |
| 2011 | 23.35M | 76.21% |
| 2010 | 13.25M | 4.24% |
| 2009 | 12.71M | 4.08% |
| 2008 | 12.21M | 6.49% |
| 2007 | 11.47M | 20.31% |
| 2006 | 9.53M | 95.56% |
| 2005 | 4.87M | 24.47% |
| 2004 | 3.92M | 10.00% |
| 2003 | 3.56M | 7.66% |
| 2002 | 3.31M | 0.59% |
| 2001 | 3.29M | 79.44% |
| 2000 | 1.83M | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| 253.90M | 16.82% |
US
|
|
| 396.00M | 82.19% |
US
|
|
| 478.91M | 120.34% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -71.39% |
NL
|
